MAP2K7 and diffuse intrinsic pontine glioma: Thus, we present evidence for a subset of patients with DIPG to harbor MAPK pathway–activating mutations, as well as sensitivity to MEK inhibition in vitro with the rapid acquisition of consistent resistance mutations, and identify potentially efficacious combination approaches based on the common mechanisms underlying these events.